Navigation Links
ABC²'s Research Showcase: INSIGhT - The First-Ever Adaptive Clinical Trial for Glioblastoma
Date:10/6/2017

On Tuesday, October 24th, ABC² (Accelerate Brain Cancer Cure) will host a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. Brian Alexander, INSIGhT Principal Investigator, Dana-Farber Cancer Institute. The event is free and open to the public, but registration is required.

WHAT: ABC² Brain Cancer Research Lunch & Learn

WHEN: October 24, 2017, 11:30 AM – 1:30 PM

WHERE: The Case Foundation, 1717 Rhode Island Ave. NW, Suite 700, Washington, DC 20036

11:30 am – 11:50 am – “Next Generation Clinical Trials and Personalized Medicine”

Speaker: Max Wallace, CEO, ABC²

11:50 am - 12:30 pm – Lunch

12:30 pm – 1:30 pm – “INSIGhT Adaptive Clinical Trial for GBM” (For those unable to attend in person, a live webcast of the discussion is scheduled to begin at 12:30 pm EST on Facebook Live)

Speakers: Dr. Brian Alexander, INSIGhT Principal Investigator, Dana-Farber Cancer Institute and David Sandak, Senior Vice President, Strategy and Research, ABC²
Moderator: Max Wallace, CEO, ABC²

INSIGhT is the first-ever adaptive clinical trial in brain cancer. It matches targeted therapies with the patients most likely to benefit from them.

Dana Farber is leading a 10-institution consortium (Massachusetts General Hospital, The University of Alabama at Birmingham, Mayo Clinic, Columbia, Cleveland Clinic, MD Anderson, University of Pittsburgh, Utah/Huntsman, and University of Virginia) that will test multiple drugs in newly diagnosed patients in a rapidly adaptive environment. Five institutions in the consortium have now begun recruiting patients and the others are soon to follow.

As part of this, ABC² has joined with three pharmaceutical companies (Eli Lilly, Celgene and Puma Biotechnology) to fund the trial and ABC²'s Allele system does the front-end molecular analysis placing patients into the treatment arm most suitable for their individual tumor.

"In the past, glioblastoma patients have faced limited treatment options and a grim prognosis," says Max Wallace, CEO of ABC². "We're focused on developing the most promising and tailored treatments for patients today - and that's the aim of INSIGhT."

To RSVP for the lunch discussion, please click HERE or email info(at)abc2(dot)org by October 13th.

2017 Science Salon Series Sponsored by Genentech

About ABC² (Accelerate Brain Cancer Cure)
ABC² is focused on speeding the discovery of a cure for brain cancer. By applying an aggressive, venture funding approach not typically seen in the nonprofit sector, ABC² closes current gaps in funding in order to catalyze research and rapidly bring new therapies to patients. ABC² has awarded more than 100 grants totaling $20 million in brain tumor research funding to highly qualified investigators and physician-scientists from 54 institutions and companies. Since its founding in 2001, ABC² has helped bring 30 different treatments into the clinic. To learn more, visit http://www.abc2.org.

# # #

Read the full story at http://www.prweb.com/releases/2017/10/prweb14765332.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. LabRoots Launches Month-long Campaign in Efforts to Push Breast Cancer Research Forward
2. ResearchDx and Menarini Silicon Biosystems Launch DEPArray HER2 for Breast and GEA Cancers
3. Central Research Laboratories® Introduces VERSA® – An Innovative, Infinitely Customizable Telemanipulator for Remote-Handling Systems
4. Thermo Fisher Scientific Advances RAS Research Panel on Applied Biosystem
5. Genedata Screener Strengthens Collaborative Research at Axxam
6. HumanZyme® Announces Human Cell-Expressed Interferon gamma for Immunology and Immunotherapy Research Applications
7. Outstanding Early-career Work Eligible for Rising Researcher Awards
8. Sterlitech to Provide Larger Scale Membrane Skids for Research and Industry Customers
9. BioPharma Institute Launches 5 Top U.S. Pharmaceutical & Clinical Research Industry Regulatory Compliance Courses as Parent Company Celebrates 20th Anniversary
10. Maryland Soybean Board Seeks Research Proposals
11. Noblis Releases Online Portal for Bioinformatics Research and Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):